Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 26 entries
Sorted by: Best Match Show Resources per page
Alpha7 nAChR Agonists for Cognitive Deficit and Negative Symptoms in Schizophrenia: A Meta-analysis of Randomized Double-blind Controlled Trials.

Shanghai archives of psychiatry

Jin Y, Wang Q, Wang Y, Liu M, Sun A, Geng Z, Lin Y, Li X.
PMID: 28955138
Shanghai Arch Psychiatry. 2017 Aug 25;29(4):191-199. doi: 10.11919/j.issn.1002-0829.217044.

BACKGROUND: Previous clinical trials of α7-nicotinic acetylcholine receptor agonists (α7-nAChR agonists) showed mixed results in treating the cognitive and negative symptoms of schizophrenia.AIMS: To assess the efficacy and safety of α7-nAChR agonists in treating the cognitive and negative symptoms...

Cite
Jin Y, Wang Q, Wang Y, et al. Alpha7 nAChR Agonists for Cognitive Deficit and Negative Symptoms in Schizophrenia: A Meta-analysis of Randomized Double-blind Controlled Trials. Shanghai Arch Psychiatry. 2017;29(4):191-199doi: 10.11919/j.issn.1002-0829.217044.
Jin, Y., Wang, Q., Wang, Y., Liu, M., Sun, A., Geng, Z., Lin, Y., & Li, X. (2017). Alpha7 nAChR Agonists for Cognitive Deficit and Negative Symptoms in Schizophrenia: A Meta-analysis of Randomized Double-blind Controlled Trials. Shanghai archives of psychiatry, 29(4), 191-199. https://doi.org/10.11919/j.issn.1002-0829.217044
Jin, Ye, et al. "Alpha7 nAChR Agonists for Cognitive Deficit and Negative Symptoms in Schizophrenia: A Meta-analysis of Randomized Double-blind Controlled Trials." Shanghai archives of psychiatry vol. 29,4 (2017): 191-199. doi: https://doi.org/10.11919/j.issn.1002-0829.217044
Jin Y, Wang Q, Wang Y, Liu M, Sun A, Geng Z, Lin Y, Li X. Alpha7 nAChR Agonists for Cognitive Deficit and Negative Symptoms in Schizophrenia: A Meta-analysis of Randomized Double-blind Controlled Trials. Shanghai Arch Psychiatry. 2017 Aug 25;29(4):191-199. doi: 10.11919/j.issn.1002-0829.217044. PMID: 28955138; PMCID: PMC5608991.
Copy Download .nbib Format: NLM
Characterization of Nicotinic Acetylcholine Receptors Expressed by Cells of the SH-SY5Y Human Neuroblastoma Clonal Line.

Molecular and cellular neurosciences

Lukas RJ, Norman SA, Lucero L.
PMID: 19912902
Mol Cell Neurosci. 1993 Feb;4(1):1-12. doi: 10.1006/mcne.1993.1001.

Radioligand binding studies show that cells of the SH-SY5Y human neuroblastoma clonal line express a single class of neuronal/nicotinic alpha-bungarotoxin binding sites (nBgtS). These sites are defined by their ability to bind radioiodinated alpha-bungarotoxin (Bgt) with high affinity (K(D)...

Cite
Lukas RJ, Norman SA, Lucero L. Characterization of Nicotinic Acetylcholine Receptors Expressed by Cells of the SH-SY5Y Human Neuroblastoma Clonal Line. Mol Cell Neurosci. 1993;4(1):1-12doi: 10.1006/mcne.1993.1001.
Lukas, R. J., Norman, S. A., & Lucero, L. (1993). Characterization of Nicotinic Acetylcholine Receptors Expressed by Cells of the SH-SY5Y Human Neuroblastoma Clonal Line. Molecular and cellular neurosciences, 4(1), 1-12. https://doi.org/10.1006/mcne.1993.1001
Lukas, R J, et al. "Characterization of Nicotinic Acetylcholine Receptors Expressed by Cells of the SH-SY5Y Human Neuroblastoma Clonal Line." Molecular and cellular neurosciences vol. 4,1 (1993): 1-12. doi: https://doi.org/10.1006/mcne.1993.1001
Lukas RJ, Norman SA, Lucero L. Characterization of Nicotinic Acetylcholine Receptors Expressed by Cells of the SH-SY5Y Human Neuroblastoma Clonal Line. Mol Cell Neurosci. 1993 Feb;4(1):1-12. doi: 10.1006/mcne.1993.1001. PMID: 19912902.
Copy Download .nbib Format: NLM
Canonical and Novel Non-Canonical Cholinergic Agonists Inhibit ATP-Induced Release of Monocytic Interleukin-1β via Different Combinations of Nicotinic Acetylcholine Receptor Subunits α7, α9 and α10.

Frontiers in cellular neuroscience

Zakrzewicz A, Richter K, Agné A, Wilker S, Siebers K, Fink B, Krasteva-Christ G, Althaus M, Padberg W, Hone AJ, McIntosh JM, Grau V.
PMID: 28725182
Front Cell Neurosci. 2017 Jul 05;11:189. doi: 10.3389/fncel.2017.00189. eCollection 2017.

Recently, we discovered a cholinergic mechanism that inhibits the adenosine triphosphate (ATP)-dependent release of interleukin-1β (IL-1β) by human monocytes via nicotinic acetylcholine receptors (nAChRs) composed of α7, α9 and/or α10 subunits. Furthermore, we identified phosphocholine (PC) and dipalmitoylphosphatidylcholine (DPPC)...

Cite
Zakrzewicz A, Richter K, Agné A, et al. Canonical and Novel Non-Canonical Cholinergic Agonists Inhibit ATP-Induced Release of Monocytic Interleukin-1β via Different Combinations of Nicotinic Acetylcholine Receptor Subunits α7, α9 and α10. Front Cell Neurosci. 2017;11:189doi: 10.3389/fncel.2017.00189.
Zakrzewicz, A., Richter, K., Agné, A., Wilker, S., Siebers, K., Fink, B., Krasteva-Christ, G., Althaus, M., Padberg, W., Hone, A. J., McIntosh, J. M., & Grau, V. (2017). Canonical and Novel Non-Canonical Cholinergic Agonists Inhibit ATP-Induced Release of Monocytic Interleukin-1β via Different Combinations of Nicotinic Acetylcholine Receptor Subunits α7, α9 and α10. Frontiers in cellular neuroscience, 11189. https://doi.org/10.3389/fncel.2017.00189
Zakrzewicz, Anna, et al. "Canonical and Novel Non-Canonical Cholinergic Agonists Inhibit ATP-Induced Release of Monocytic Interleukin-1β via Different Combinations of Nicotinic Acetylcholine Receptor Subunits α7, α9 and α10." Frontiers in cellular neuroscience vol. 11 (2017): 189. doi: https://doi.org/10.3389/fncel.2017.00189
Zakrzewicz A, Richter K, Agné A, Wilker S, Siebers K, Fink B, Krasteva-Christ G, Althaus M, Padberg W, Hone AJ, McIntosh JM, Grau V. Canonical and Novel Non-Canonical Cholinergic Agonists Inhibit ATP-Induced Release of Monocytic Interleukin-1β via Different Combinations of Nicotinic Acetylcholine Receptor Subunits α7, α9 and α10. Front Cell Neurosci. 2017 Jul 05;11:189. doi: 10.3389/fncel.2017.00189. eCollection 2017. PMID: 28725182; PMCID: PMC5496965.
Copy Download .nbib Format: NLM
Acetylcholine receptor subunit and P-glycoprotein transcription patterns in levamisole-susceptible and -resistant Haemonchus contortus.

International journal for parasitology. Drugs and drug resistance

Sarai RS, Kopp SR, Coleman GT, Kotze AC.
PMID: 24533293
Int J Parasitol Drugs Drug Resist. 2013 Feb 01;3:51-8. doi: 10.1016/j.ijpddr.2013.01.002. eCollection 2013 Dec.

The mechanism of resistance to the anthelmintic levamisole in parasitic nematodes is poorly understood, although there is some evidence implicating changes in expression of nicotinic acetylcholine receptor (nAChR) subunit genes. Hence, in order to define levamisole resistance mechanisms in...

Cite
Sarai RS, Kopp SR, Coleman GT, et al. Acetylcholine receptor subunit and P-glycoprotein transcription patterns in levamisole-susceptible and -resistant Haemonchus contortus. Int J Parasitol Drugs Drug Resist. 2013;3:51-8doi: 10.1016/j.ijpddr.2013.01.002.
Sarai, R. S., Kopp, S. R., Coleman, G. T., & Kotze, A. C. (2013). Acetylcholine receptor subunit and P-glycoprotein transcription patterns in levamisole-susceptible and -resistant Haemonchus contortus. International journal for parasitology. Drugs and drug resistance, 351-8. https://doi.org/10.1016/j.ijpddr.2013.01.002
Sarai, Ranbir S, et al. "Acetylcholine receptor subunit and P-glycoprotein transcription patterns in levamisole-susceptible and -resistant Haemonchus contortus." International journal for parasitology. Drugs and drug resistance vol. 3 (2013): 51-8. doi: https://doi.org/10.1016/j.ijpddr.2013.01.002
Sarai RS, Kopp SR, Coleman GT, Kotze AC. Acetylcholine receptor subunit and P-glycoprotein transcription patterns in levamisole-susceptible and -resistant Haemonchus contortus. Int J Parasitol Drugs Drug Resist. 2013 Feb 01;3:51-8. doi: 10.1016/j.ijpddr.2013.01.002. eCollection 2013 Dec. PMID: 24533293; PMCID: PMC3862433.
Copy Download .nbib Format: NLM
Emerging Pharmacological Properties of Cholinergic Synaptic Transmission: Comparison between Mammalian and Insect Synaptic and Extrasynaptic Nicotinic Receptors.

Current neuropharmacology

Thany SH, Tricoire-Leignel H.
PMID: 22654728
Curr Neuropharmacol. 2011 Dec;9(4):706-14. doi: 10.2174/157015911798376343.

Acetylcholine (ACh) is probably the oldest signalling neurotransmitter which appeared in evolution before the nervous system. It is present in bacteria, algae, protozoa and plants. In insects and mammals it is involved in cell-to-cell communications in various neuronal and...

Cite
Thany SH, Tricoire-Leignel H. Emerging Pharmacological Properties of Cholinergic Synaptic Transmission: Comparison between Mammalian and Insect Synaptic and Extrasynaptic Nicotinic Receptors. Curr Neuropharmacol. 2011;9(4):706-14doi: 10.2174/157015911798376343.
Thany, S. H., & Tricoire-Leignel, H. (2011). Emerging Pharmacological Properties of Cholinergic Synaptic Transmission: Comparison between Mammalian and Insect Synaptic and Extrasynaptic Nicotinic Receptors. Current neuropharmacology, 9(4), 706-14. https://doi.org/10.2174/157015911798376343
Thany, Steeve H, and Tricoire-Leignel, Hélène. "Emerging Pharmacological Properties of Cholinergic Synaptic Transmission: Comparison between Mammalian and Insect Synaptic and Extrasynaptic Nicotinic Receptors." Current neuropharmacology vol. 9,4 (2011): 706-14. doi: https://doi.org/10.2174/157015911798376343
Thany SH, Tricoire-Leignel H. Emerging Pharmacological Properties of Cholinergic Synaptic Transmission: Comparison between Mammalian and Insect Synaptic and Extrasynaptic Nicotinic Receptors. Curr Neuropharmacol. 2011 Dec;9(4):706-14. doi: 10.2174/157015911798376343. PMID: 22654728; PMCID: PMC3263464.
Copy Download .nbib Format: NLM
Monoclonal antibodies against ?-bungarotoxin.

Neurochemistry international

Quik M, Geertsen S, Kenigsberg RL, Cuello AC.
PMID: 20504554
Neurochem Int. 1990;16(2):163-71. doi: 10.1016/0197-0186(90)90084-7.

Hybridomas secreting monoclonal antibodies against ?-bungarotoxin were produced from the fusions of mice lymphocytes from hyperimmune animals with two mice myeloma cell lines ((NSI/1 or Sp2/0). Several anti-?-bungarotoxin monoclonal antibodies were derived and characterized. One of these (spB57) belonged...

Cite
Quik M, Geertsen S, Kenigsberg RL, et al. Monoclonal antibodies against ?-bungarotoxin. Neurochem Int. 1990;16(2):163-71doi: 10.1016/0197-0186(90)90084-7.
Quik, M., Geertsen, S., Kenigsberg, R. L., & Cuello, A. C. (1990). Monoclonal antibodies against ?-bungarotoxin. Neurochemistry international, 16(2), 163-71. https://doi.org/10.1016/0197-0186(90)90084-7
Quik, M, et al. "Monoclonal antibodies against ?-bungarotoxin." Neurochemistry international vol. 16,2 (1990): 163-71. doi: https://doi.org/10.1016/0197-0186(90)90084-7
Quik M, Geertsen S, Kenigsberg RL, Cuello AC. Monoclonal antibodies against ?-bungarotoxin. Neurochem Int. 1990;16(2):163-71. doi: 10.1016/0197-0186(90)90084-7. PMID: 20504554.
Copy Download .nbib Format: NLM
In vivo pharmacological profile of substituted (3-pyridyl)-2-phenylisoxazolidine analogues of nicotine as novel antinociceptives.

Research in pharmaceutical sciences

Sethi N, Bhatti R, Ishar MP.
PMID: 25598800
Res Pharm Sci. 2014 Jan-Feb;9(1):59-67.

Nicotinic ligands have been studied as novel therapeutic interventions in pain therapeutics since a long time. Several nicotinic agonists have been withdrawn from later stages of clinical trials due to lack of efficacy or narrow therapeutic window. These have...

Cite
Sethi N, Bhatti R, Ishar MP. In vivo pharmacological profile of substituted (3-pyridyl)-2-phenylisoxazolidine analogues of nicotine as novel antinociceptives. Res Pharm Sci. 2014;9(1):59-67
Sethi, N., Bhatti, R., & Ishar, M. P. (2014). In vivo pharmacological profile of substituted (3-pyridyl)-2-phenylisoxazolidine analogues of nicotine as novel antinociceptives. Research in pharmaceutical sciences, 9(1), 59-67.
Sethi, N, et al. "In vivo pharmacological profile of substituted (3-pyridyl)-2-phenylisoxazolidine analogues of nicotine as novel antinociceptives." Research in pharmaceutical sciences vol. 9,1 (2014): 59-67.
Sethi N, Bhatti R, Ishar MP. In vivo pharmacological profile of substituted (3-pyridyl)-2-phenylisoxazolidine analogues of nicotine as novel antinociceptives. Res Pharm Sci. 2014 Jan-Feb;9(1):59-67. PMID: 25598800; PMCID: PMC4292182.
Copy Download .nbib Format: NLM
Insights into the mechanism by which atropine inhibits myopia: evidence against cholinergic hyperactivity and modulation of dopamine release.

British journal of pharmacology

Thomson K, Kelly T, Karouta C, Morgan I, Ashby R.
PMID: 34302355
Br J Pharmacol. 2021 Nov;178(22):4501-4517. doi: 10.1111/bph.15629. Epub 2021 Oct 10.

BACKGROUND AND PURPOSE: The ability of the muscarinic cholinergic antagonist atropine to inhibit myopia development in humans and animal models would suggest that cholinergic hyperactivity may underlie myopic growth. To test this, we investigated whether cholinergic agonists accelerate ocular...

Cite
Thomson K, Kelly T, Karouta C, et al. Insights into the mechanism by which atropine inhibits myopia: evidence against cholinergic hyperactivity and modulation of dopamine release. Br J Pharmacol. 2021;178(22):4501-4517doi: 10.1111/bph.15629.
Thomson, K., Kelly, T., Karouta, C., Morgan, I., & Ashby, R. (2021). Insights into the mechanism by which atropine inhibits myopia: evidence against cholinergic hyperactivity and modulation of dopamine release. British journal of pharmacology, 178(22), 4501-4517. https://doi.org/10.1111/bph.15629
Thomson, Kate, et al. "Insights into the mechanism by which atropine inhibits myopia: evidence against cholinergic hyperactivity and modulation of dopamine release." British journal of pharmacology vol. 178,22 (2021): 4501-4517. doi: https://doi.org/10.1111/bph.15629
Thomson K, Kelly T, Karouta C, Morgan I, Ashby R. Insights into the mechanism by which atropine inhibits myopia: evidence against cholinergic hyperactivity and modulation of dopamine release. Br J Pharmacol. 2021 Nov;178(22):4501-4517. doi: 10.1111/bph.15629. Epub 2021 Oct 10. PMID: 34302355.
Copy Download .nbib Format: NLM
Utilization of computer processed high definition video imaging for measuring motility of microscopic nematode stages on a quantitative scale: "The Worminator".

International journal for parasitology. Drugs and drug resistance

Storey B, Marcellino C, Miller M, Maclean M, Mostafa E, Howell S, Sakanari J, Wolstenholme A, Kaplan R.
PMID: 25516834
Int J Parasitol Drugs Drug Resist. 2014 Aug 28;4(3):233-43. doi: 10.1016/j.ijpddr.2014.08.003. eCollection 2014 Dec.

A major hindrance to evaluating nematode populations for anthelmintic resistance, as well as for screening existing drugs, new compounds, or bioactive plant extracts for anthelmintic properties, is the lack of an efficient, objective, and reproducible in vitro assay that...

Cite
Storey B, Marcellino C, Miller M, et al. Utilization of computer processed high definition video imaging for measuring motility of microscopic nematode stages on a quantitative scale: "The Worminator". Int J Parasitol Drugs Drug Resist. 2014;4(3):233-43doi: 10.1016/j.ijpddr.2014.08.003.
Storey, B., Marcellino, C., Miller, M., Maclean, M., Mostafa, E., Howell, S., Sakanari, J., Wolstenholme, A., & Kaplan, R. (2014). Utilization of computer processed high definition video imaging for measuring motility of microscopic nematode stages on a quantitative scale: "The Worminator". International journal for parasitology. Drugs and drug resistance, 4(3), 233-43. https://doi.org/10.1016/j.ijpddr.2014.08.003
Storey, Bob, et al. "Utilization of computer processed high definition video imaging for measuring motility of microscopic nematode stages on a quantitative scale: "The Worminator"." International journal for parasitology. Drugs and drug resistance vol. 4,3 (2014): 233-43. doi: https://doi.org/10.1016/j.ijpddr.2014.08.003
Storey B, Marcellino C, Miller M, Maclean M, Mostafa E, Howell S, Sakanari J, Wolstenholme A, Kaplan R. Utilization of computer processed high definition video imaging for measuring motility of microscopic nematode stages on a quantitative scale: "The Worminator". Int J Parasitol Drugs Drug Resist. 2014 Aug 28;4(3):233-43. doi: 10.1016/j.ijpddr.2014.08.003. eCollection 2014 Dec. PMID: 25516834; PMCID: PMC4266792.
Copy Download .nbib Format: NLM
Density of α4β2* nAChR on the surface of neurons is modulated by chronic antagonist exposure.

Pharmacology research & perspectives

Zambrano CA, Short CA, Salamander RM, Grady SR, Marks MJ.
PMID: 25729578
Pharmacol Res Perspect. 2015 Mar;3(2):e00111. doi: 10.1002/prp2.111.

The expression of high-affinity α4β2* nicotinic acetylcholine receptors (nAChR) increases following chronic exposure to nicotinic agonists. While, nAChR antagonists can also produce upregulation, these changes are often less pronounced than achieved with agonists. It is unknown if nAChR agonists...

Cite
Zambrano CA, Short CA, Salamander RM, et al. Density of α4β2* nAChR on the surface of neurons is modulated by chronic antagonist exposure. Pharmacol Res Perspect. 2015;3(2):e00111doi: 10.1002/prp2.111.
Zambrano, C. A., Short, C. A., Salamander, R. M., Grady, S. R., & Marks, M. J. (2015). Density of α4β2* nAChR on the surface of neurons is modulated by chronic antagonist exposure. Pharmacology research & perspectives, 3(2), e00111. https://doi.org/10.1002/prp2.111
Zambrano, Cristian A, et al. "Density of α4β2* nAChR on the surface of neurons is modulated by chronic antagonist exposure." Pharmacology research & perspectives vol. 3,2 (2015): e00111. doi: https://doi.org/10.1002/prp2.111
Zambrano CA, Short CA, Salamander RM, Grady SR, Marks MJ. Density of α4β2* nAChR on the surface of neurons is modulated by chronic antagonist exposure. Pharmacol Res Perspect. 2015 Mar;3(2):e00111. doi: 10.1002/prp2.111. PMID: 25729578; PMCID: PMC4324685.
Copy Download .nbib Format: NLM
Cognitive Enhancers in Schizophrenia: A Systematic Review and Meta-Analysis of Alpha-7 Nicotinic Acetylcholine Receptor Agonists for Cognitive Deficits and Negative Symptoms.

Frontiers in psychiatry

Recio-Barbero M, Segarra R, Zabala A, González-Fraile E, González-Pinto A, Ballesteros J.
PMID: 33889097
Front Psychiatry. 2021 Apr 06;12:631589. doi: 10.3389/fpsyt.2021.631589. eCollection 2021.

No abstract available.

Cite
Recio-Barbero M, Segarra R, Zabala A, et al. Cognitive Enhancers in Schizophrenia: A Systematic Review and Meta-Analysis of Alpha-7 Nicotinic Acetylcholine Receptor Agonists for Cognitive Deficits and Negative Symptoms. Front Psychiatry. 2021;12:631589doi: 10.3389/fpsyt.2021.631589.
Recio-Barbero, M., Segarra, R., Zabala, A., González-Fraile, E., González-Pinto, A., & Ballesteros, J. (2021). Cognitive Enhancers in Schizophrenia: A Systematic Review and Meta-Analysis of Alpha-7 Nicotinic Acetylcholine Receptor Agonists for Cognitive Deficits and Negative Symptoms. Frontiers in psychiatry, 12631589. https://doi.org/10.3389/fpsyt.2021.631589
Recio-Barbero, María, et al. "Cognitive Enhancers in Schizophrenia: A Systematic Review and Meta-Analysis of Alpha-7 Nicotinic Acetylcholine Receptor Agonists for Cognitive Deficits and Negative Symptoms." Frontiers in psychiatry vol. 12 (2021): 631589. doi: https://doi.org/10.3389/fpsyt.2021.631589
Recio-Barbero M, Segarra R, Zabala A, González-Fraile E, González-Pinto A, Ballesteros J. Cognitive Enhancers in Schizophrenia: A Systematic Review and Meta-Analysis of Alpha-7 Nicotinic Acetylcholine Receptor Agonists for Cognitive Deficits and Negative Symptoms. Front Psychiatry. 2021 Apr 06;12:631589. doi: 10.3389/fpsyt.2021.631589. eCollection 2021. PMID: 33889097; PMCID: PMC8055861.
Copy Download .nbib Format: NLM
FDA position statement "Early Alzheimer's disease: Developing drugs for treatment, Guidance for Industry".

Alzheimer's & dementia (New York, N. Y.)

Sabbagh MN, Hendrix S, Harrison JE.
PMID: 31650002
Alzheimers Dement (N Y). 2019 Jan 10;5:13-19. doi: 10.1016/j.trci.2018.11.004. eCollection 2019.

Despite billions of dollars invested in clinical trials to develop novel therapeutics for Alzheimer's disease, no approved treatments have been developed in the past 15 years. In that span, new classes of drugs have been developed and tested, including...

Cite
Sabbagh MN, Hendrix S, Harrison JE. FDA position statement "Early Alzheimer's disease: Developing drugs for treatment, Guidance for Industry". Alzheimers Dement (N Y). 2019;5:13-19doi: 10.1016/j.trci.2018.11.004.
Sabbagh, M. N., Hendrix, S., & Harrison, J. E. (2019). FDA position statement "Early Alzheimer's disease: Developing drugs for treatment, Guidance for Industry". Alzheimer's & dementia (New York, N. Y.), 513-19. https://doi.org/10.1016/j.trci.2018.11.004
Sabbagh, Marwan N, et al. "FDA position statement "Early Alzheimer's disease: Developing drugs for treatment, Guidance for Industry"." Alzheimer's & dementia (New York, N. Y.) vol. 5 (2019): 13-19. doi: https://doi.org/10.1016/j.trci.2018.11.004
Sabbagh MN, Hendrix S, Harrison JE. FDA position statement "Early Alzheimer's disease: Developing drugs for treatment, Guidance for Industry". Alzheimers Dement (N Y). 2019 Jan 10;5:13-19. doi: 10.1016/j.trci.2018.11.004. eCollection 2019. PMID: 31650002; PMCID: PMC6804505.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 26 entries